Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invivyd ( (IVVD) ) just unveiled an update.
On October 30, 2025, Invivyd, Inc. released an investor presentation highlighting their ongoing efforts in antibody development for viral threats, particularly COVID-19. The presentation underscored the challenges posed by COVID-19 variants and the company’s strategic focus on monoclonal antibodies to address these challenges. Invivyd’s initiatives aim to enhance the durability and effectiveness of antibody-based treatments, reflecting their commitment to overcoming the limitations of current vaccines and addressing stakeholder concerns about vaccine efficacy and safety.
The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. operates in the biotechnology industry, focusing on developing advanced antibody treatments and protections against viral threats. Their primary products include monoclonal antibodies like PEMGARDA® (pemivibart) and VYD2311, with a market focus on COVID-19, Long COVID, RSV, and measles.
Average Trading Volume: 7,461,212
Technical Sentiment Signal: Buy
Current Market Cap: $411.7M
Find detailed analytics on IVVD stock on TipRanks’ Stock Analysis page.